Thanks to years of work by dedicated researchers at the University of Kansas Medical Center, adults with the most common form of polycystic kidney disease now have an approved medicine to slow the progress of the disease.  The medicine, JYNARQUE™ (pronounced jin-AR-kew) was approved this past week as the first medicine available for these adult patients.  The medicine helps delay the slide of PKD patients to kidney failure or kidney transplant.  The major push to develop research of PKD began on the medical center campus with Dr. Jared Grantham, who helped establish both the center’s Kidney Institute and the PKD Foundation here in Kansas City.  Dr. Alan Yu, nephrologist with the University of Kansas Medical Center, led a team through clinical trials for the drug.  In the video, Dr. Yu says the drug is very important for his patients, but it is also a source of pride for the medical center research team.